10583 studies found for:    NCI
Show Display Options
Rank Status Study
21 Completed O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: O6-benzylguanine;   Drug: carmustine
22 Active, not recruiting Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
Condition: Adult Solid Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pegfilgrastim;   Other: Pharmacological Study;   Drug: Tivantinib;   Drug: Topotecan Hydrochloride
23 Completed Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Drug: arsenic trioxide;   Radiation: radiation therapy
24 Completed
Has Results
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Intervention: Drug: irofulven
25 Completed Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Azacitidine;   Drug: Entinostat;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
26 Completed
Has Results
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
Condition: Precancerous Condition
Interventions: Other: placebo;   Drug: eflornithine;   Drug: sulindac;   Other: laboratory biomarker analysis
27 Terminated Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer
Conditions: Liver Metastases;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Drug: oxaliplatin;   Drug: capecitabine;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
28 Active, not recruiting Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Veliparib
29 Not yet recruiting Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
Conditions: Diffuse Intrinsic Pontine Glioma;   Malignant Glioma;   Recurrent Childhood Brain Neoplasm
Interventions: Procedure: Diffusion Tensor Imaging;   Procedure: Diffusion Weighted Imaging;   Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging;   Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging;   Other: Laboratory Biomarker Analysis;   Procedure: Magnetic Resonance Spectroscopic Imaging;   Biological: Pembrolizumab;   Procedure: Perfusion Magnetic Resonance Imaging
30 Completed Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
Condition: Stage IIIA Non-small Cell Lung Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: motexafin gadolinium;   Procedure: conventional surgery;   Radiation: radiation therapy
31 Suspended Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
Conditions: Endometrial Clear Cell Adenocarcinoma;   Estrogen Receptor Negative;   Ovarian Clear Cell Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Drug: Dasatinib;   Other: Laboratory Biomarker Analysis
32 Completed
Has Results
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
Conditions: Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Intervention: Drug: lenalidomide
33 Terminated
Has Results
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Intervention: Drug: romidepsin
34 Completed Immunotoxin in Treating Patients With Leukemia or Lymphoma
Conditions: Leukemia;   Lymphoma
Intervention: Biological: LMB-2 immunotoxin
35 Completed
Has Results
Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
Conditions: Adult Synovial Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Other: diagnostic laboratory biomarker analysis;   Drug: everolimus;   Drug: imatinib mesylate
36 Completed Vaccine Therapy in Treating Patients With Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: dendritic cell-MART-1 peptide vaccine;   Biological: gp100 antigen;   Biological: therapeutic tumor infiltrating lymphocytes;   Biological: tyrosinase peptide
37 Terminated
Has Results
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer;   Tumors Metastatic to Brain
Interventions: Drug: erlotinib hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: stereotactic radiosurgery;   Drug: temozolomide
38 Completed
Has Results
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Gastric Cancer;   Stage IIIA Gastric Cancer;   Stage IIIB Gastric Cancer;   Stage IIIC Gastric Cancer;   Stage IV Gastric Cancer
Interventions: Drug: alvocidib;   Drug: irinotecan hydrochloride;   Other: laboratory biomarker analysis
39 Completed
Has Results
S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Capecitabine;   Drug: Imatinib mesylate
40 Terminated Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer
Conditions: Ovarian Dysgerminoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Ovarian Germ Cell Tumor;   Stage II Malignant Testicular Germ Cell Tumor;   Stage II Ovarian Germ Cell Tumor;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Ovarian Germ Cell Tumor;   Testicular Seminoma
Interventions: Drug: imatinib mesylate;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years